- Home
- JBDI vs ABP Comparison
JBDI vs ABP Comparison
Compare JBDI & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | ABP |
|---|---|---|
| Founded | 1983 | 2004 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 12.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | JBDI | ABP |
|---|---|---|
| Price | $0.65 | $3.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 94.1K | 10.7K |
| Earning Date | 01-01-0001 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,445,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $0.49 | $3.56 |
| 52 Week High | $3.00 | $42.90 |
Technical Indicators
Market Signals| Indicator | JBDI | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 32.76 |
| Support Level | $0.68 | $3.82 |
| Resistance Level | $0.80 | $4.11 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 4.78 | 5.93 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.